We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Digital Pathology Solution Now Customized for Breast Cancer Diagnostics

By LabMedica International staff writers
Posted on 09 Sep 2013
A tissue-staining analysis tool has been made accessible within a digital pathology system and has been customized for breast cancer biomarkers.

Dako Denmark A/S (Glostrup, Denmark), an Agilent Technologies company, and Omnyx, LLC (Pittsbugh, PA, USA), a joint venture of General Electric Healthcare and the University of Pittsburgh Medical Center, are now providing a newly developed clinical image analysis system for digital pathology in Europe. More...
Dako has been using its expertise in staining and image analysis to develop algorithms that are incorporated into the Omnyx integrated digital pathology platform as part of Omnyx’s aim of providing pathologists with a comprehensive workflow. Now, also Dako’s “HercepTest” image analysis tool for tissue-stained slides is accessible in the Omnyx system and specifically customized for Dako’s breast cancer prognostic markers.

HercepTest is a semiquantitative immunohistochemical assay for specific determination of HER2 (c-erbB-2 onco-protein) overexpression. It is used for breast cancer tissues routinely processed for histological evaluation; also for formalin-fixed, paraffin-embedded (FFPE) cancer tissue from patients with metastatic gastric or gastroesophageal junction adenocarcinoma. HercepTest is indicated as an aid in the assessment of breast and gastric cancer patients for whom trastuzumab (Herceptin) treatment is being considered, and for breast cancer patients for whom pertuzumab (PERJETA) or ado-trastuzumab emtansine (KADCYLA) treatment is being considered.

By providing quantitative, reproducible results and more objective interpretation for HercepTest, the combined system improves accuracy and efficiency and enables a more confident diagnosis. “Omnyx envisions a future where image analysis and workflow empower pathologists to make confident clinical decisions ultimately leading to better patient care,” said Jim LaFrance, CEO of Omnyx. “Our partnership with Dako allows us to offer image analysis to clinicians who use Dako tests.”

Digital pathology holds much potential for standardizing test interpretation and enabling greater accuracy in tissue-based diagnostics. “With this offering, Dako and Omnyx support pathologists in making confident, efficient diagnoses based on both subjective and quantitative measures,” said Jakob Mohr Christensen, vice president of Global Marketing at Dako; “Additionally, the algorithms link digital scanners to Dako reagents and staining instruments, [providing] a complete and integrated solution.”

Related Links:

Omnyx, LLC
Dako



Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Influenza Virus Test
NovaLisa Influenza Virus B IgM ELISA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.